ABSTRACT OBJECTIVES This study sought to report the late multimodality imaging and clinical outcomes of the novel poly-L-lactic-acid-based DESolve novolimus-eluting bioresorbable coronary scaffold for the treatment of de novo coronary lesions.
DESolve scaffold uses a balloon-expandable delivery system that is 0.014-inch diameter guidewire and 6-F guide catheter compatible. The device should be stored at 0 C to 8 C.
PROCEDURE. By protocol, treatment of up to 2 de novo coronary lesions in separate major epicardial vessels was allowed; only 1 target lesion was considered for treatment with the study device. When applicable, the first lesion, designated as non-target, was treated with an approved "limus" drug-eluting stent. If optimally treated, the target lesion was approached. Pre-dilation was mandatory. The DESolve scaffold was available in the 3.0-, 3.25-, and 3.5-mm diameters, and 14-and 18-mm lengths. After lesion access and cross, the scaffold was slowly Abizaid et al. Appendix.
An independent clinical research organization was responsible for the overall data collection and analysis, study management, monitoring, and QCA, IVUS, Abizaid et al. This patient remained asymptomatic without further clinical complications through hospital discharge.
Six-month angiography showed a patent stent, and the patient remained asymptomatic through 24 months. There was no autopsy, and the event was adjudicated as a cardiac death and subacute, probable thrombosis (14) . The cumulative MACE rate at 6 months was 3.3%, including 2 target lesion revascularizations (Table 3) 
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non-target vessel revascularization on day 454, evolving to acute cardiac failure, pulmonary insufficiency, and death on day 469; the target lesion was patent; and 1 additional target lesion revascularization due to a significant in-scaffold stenosis. Thus, at 24 months, the MACE rate was 7.4%.
Paired analyses for IVUS and OCT were completed in a subset of 40 and 38 patients, respectively (Table 4) . By IVUS, there were 3 cases of acute incomplete strut apposition; at the 6-month evalua- Abizaid et al. 
